AHK-Cu vs CJC-1295 (without DAC)
Well Studied vs Well Studied
synergistic Mechanism-based · 47% AHK-Cu and CJC-1295 (without DAC) work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
AHK-Cu CJC-1295 (without DAC)
Weight 416.9 Da 3,367.97 Da
Half-life Not established 30 minutes - 2 hours
Chain 3 amino acids 30 amino acids
Type Copper tripeptide complex GHRH analog
Key Benefits
AHK-Cu
01 Hair follicle elongation stimulation
02 Dermal papilla cell proliferation
03 VEGF upregulation for improved scalp circulation
04 TGF-β1 reduction (counters DHT effects)
05 Anti-apoptotic protection for follicles
06 Collagen synthesis support
07 Convenient topical application
08 Fibroblast activation for skin regeneration
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Dosing Protocols
AHK-Cu
0.5-1% topical solution/serum / Once or twice daily application
Mesotherapy - Scalp (Practitioner) 0.1-0.5 mg per injection site Weekly sessions
Research Protocol 1-5 mg 2-3 times weekly
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Side Effects
AHK-Cu
Generally well-tolerated with excellent safety profile in topical applications
Rare scalp irritation (patch test recommended)
Potential for mild redness on sensitive skin
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Contraindications
Not for use on broken or infected skin
Avoid eye area - may cause irritation
Do not use if allergic to copper or peptides
Not recommended during acute skin infections
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Research Evidence
AHK-Cu CJC-1295 (without DAC)
Status Well Studied Well Studied
References 4 studies 5 studies
Latest March 2025 November 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.